-
Je něco špatně v tomto záznamu ?
Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer
P. Faltejskova, O. Bocanek, M. Sachlova, M. Svoboda, I. Kiss, R. Vyzula, O. Slaby,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT13549
MZ0
CEP - Centrální evidence projektů
PubMed
23568010
DOI
10.3233/cbm-130308
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- kolorektální nádory krev diagnóza MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikro RNA krev MeSH
- nádorové biomarkery krev MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the world. Therefore, there is a high demand for cost-effective and non-invasive biomarkers that would enable an early detection of asymptomatic and curable disease with high sensitivity and specificity. OBJECTIVE: The main objective of this study was to investigate the potential of circulating miRNAs as biomarkers of CRC. METHODS: Total RNA enriched for small RNAs was isolated from 100~sera of patients with CRC and 30 sera of healthy donors. The expression levels of miR-17-3p, miR-29a, miR-92a and miR-135b were determined using quantitative real-time PCR. The average expression levels of particular miRNAs were normalized to miR-16 levels and statistically evaluated. RESULTS: Using Mann-Whitney U test, no significant differences were observed in miR-17-3p (P=0.18), miR-29a (P=0.14) and miR-92a (P=0.60) levels between sera of CRC patients and controls. The levels of miR-135b in serum were too low to be quantified accurately. Subsequently, we tried to correlate expression levels of analyzed miRNAs to clinical-pathological features of CRC patients. Only levels of mir-29a were correlated with the clinical stage (P=0.04). Expression levels of the other miRNAs were correlated neither with the clinical stage, nor with the grade. CONCLUSIONS: Interestingly, our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031945
- 003
- CZ-PrNML
- 005
- 20191011091912.0
- 007
- ta
- 008
- 131002s2012 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3233/CBM-130308 $2 doi
- 035 __
- $a (PubMed)23568010
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Vychytilová, Petra, $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. $d 1987- $7 xx0165184
- 245 10
- $a Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer / $c P. Faltejskova, O. Bocanek, M. Sachlova, M. Svoboda, I. Kiss, R. Vyzula, O. Slaby,
- 520 9_
- $a BACKGROUND: Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the world. Therefore, there is a high demand for cost-effective and non-invasive biomarkers that would enable an early detection of asymptomatic and curable disease with high sensitivity and specificity. OBJECTIVE: The main objective of this study was to investigate the potential of circulating miRNAs as biomarkers of CRC. METHODS: Total RNA enriched for small RNAs was isolated from 100~sera of patients with CRC and 30 sera of healthy donors. The expression levels of miR-17-3p, miR-29a, miR-92a and miR-135b were determined using quantitative real-time PCR. The average expression levels of particular miRNAs were normalized to miR-16 levels and statistically evaluated. RESULTS: Using Mann-Whitney U test, no significant differences were observed in miR-17-3p (P=0.18), miR-29a (P=0.14) and miR-92a (P=0.60) levels between sera of CRC patients and controls. The levels of miR-135b in serum were too low to be quantified accurately. Subsequently, we tried to correlate expression levels of analyzed miRNAs to clinical-pathological features of CRC patients. Only levels of mir-29a were correlated with the clinical stage (P=0.04). Expression levels of the other miRNAs were correlated neither with the clinical stage, nor with the grade. CONCLUSIONS: Interestingly, our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a kolorektální nádory $x krev $x diagnóza $7 D015179
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x krev $7 D035683
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bocanek, Ondrej $u -
- 700 1_
- $a Šachlová, Milana, $u - $d 1959- $7 mzk2006322883
- 700 1_
- $a Svoboda, Marek, $u - $d 1975- $7 xx0098478
- 700 1_
- $a Kiss, Igor, $u - $d 1965- $7 xx0031864
- 700 1_
- $a Vyzula, Rostislav, $u - $d 1952- $7 nlk20000083661
- 700 1_
- $a Slabý, Ondřej, $u - $d 1981- $7 js20030220015
- 773 0_
- $w MED00173146 $t Cancer biomarkers : section A of Disease markers $x 1875-8592 $g Roč. 12, č. 4 (2012), s. 199-204
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23568010 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20191011092332 $b ABA008
- 999 __
- $a ok $b bmc $g 996032 $s 830390
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 12 $c 4 $d 199-204 $i 1875-8592 $m Disease markers. Section A, Cancer Biomarkers $n Cancer Biomark $x MED00173146
- GRA __
- $a NT13549 $p MZ0
- LZP __
- $a Pubmed-20131002